2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow JM-010: new trials by email Literature Review of JM-010 trials Research Report on JM-010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of ASTORIA JM-010 - Dyskinesias | Phase 2 | Terminated | Contera Pharma A/S | 6 | 2024-01-19 | 2024-10-15 |
| A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia JM-010 group A, JM-010 group B, Placebos - Dyskinesias | Phase 2 | Completed | Contera Pharma | 89 | 2019-07-22 | 2024-06-17 |
| Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia JM-010, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 2 | Completed | Bukwang Pharmaceutical | 30 | 2015-05-01 | 2016-01-13 |
Dyskinesias (3) · Parkinson Disease (1)
Bukwang Pharmaceutical (1) · Contera Pharma (1) · Contera Pharma A/S (1)
Italy (2) · Spain (2) · France (1) · Germany (1) · South Africa (1) · South Korea (1)
2017 (1)